Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $181.33 Average PT from Analysts

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been given a consensus rating of "Buy" by the twenty-two research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a hold recommendation, twenty have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $181.33.

Several analysts have recently commented on the company. Cantor Fitzgerald raised Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $152.00 to $167.00 in a research report on Thursday, November 7th. Guggenheim upped their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Raymond James reaffirmed an "outperform" rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. Needham & Company LLC reaffirmed a "buy" rating and issued a $205.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, November 7th. Finally, UBS Group boosted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers purchased 37,038 shares of the company's stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Institutional Trading of Sarepta Therapeutics

Several institutional investors have recently bought and sold shares of SRPT. Innealta Capital LLC acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at $31,000. New Covenant Trust Company N.A. acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth approximately $32,000. Huntington National Bank raised its stake in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after acquiring an additional 175 shares during the last quarter. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Finally, Riggs Asset Managment Co. Inc. grew its position in Sarepta Therapeutics by 33.3% during the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock worth $47,000 after acquiring an additional 75 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Sarepta Therapeutics Trading Down 3.0 %

Shares of NASDAQ:SRPT traded down $3.52 during mid-day trading on Tuesday, hitting $114.32. The stock had a trading volume of 1,110,094 shares, compared to its average volume of 1,233,550. The company's 50 day moving average is $125.56 and its 200-day moving average is $132.90. Sarepta Therapeutics has a 12-month low of $76.61 and a 12-month high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.19 and a current ratio of 3.84. The company has a market cap of $10.92 billion, a PE ratio of 94.27 and a beta of 0.81.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.